NeuroMab™ Anti-Alpha Synuclein Antibody (NRP-0422-P618)

Figure 1 Recombinant human α-synuclein antibodies against different epitopes.

Recombinant full-length and truncated α-synuclein were coated onto ELISA plates at the same coating concentration (20 μg/ml).

Figure 2 Recombinant human α-synuclein antibody binds α-synuclein but not β- and γ-synuclein in a direct ELISA.

Recombinant α-, β- and γ-synuclein coated onto ELISA plates at the same coating concentration (2 μg/ml) together with recombinant human α-synuclein antibody or pan-synuclein antibody Incubation.

Figure 3 Recombinant human α-synuclein antibody NI-202.12F4 binds α-synuclein but not β- and γ-synuclein in Western blot analysis.

Recombinant α-, β- and γ-synuclein (750 ng each) were subjected to SDS-PAGE followed by Western blot analysis.

Figure 4. Recombinant NI-202.12F4 shows high affinity binding to wild-type and pathogenic α-synuclein mutants.

Recombinant wild type (●), A53T (▪), A30P (*) and E64K (⋄Human α-synuclein was coated on ELISA plates (2 μg/ml) and probed with different concentrations of NI202.12F4.

Figure 5 Chronic treatment with NI-202.12F4 improved the locomotor capacity of α-synuclein A53T transgenic mice.

The time required to turn down was significantly reduced in NI-202.12F4-treated animals (t-turn; 1.7±0.3 vs. 4.6±0.6 s, p=0.0002, two-tailed Student's t-test).

Figure 6 Chronic treatment of α-synuclein A53T transgenic mice with NI-202.12F4 results in increased plasma levels of human A53T α-synuclein.

Plasma samples were prepared from 12.5-month-old α-synuclein A53T transgenic mice treated with weekly intraperitoneal injections of 5 mg/kg NI-202.12F4 or PBS for 2 months. Blood was collected 24 hours after the last application.